Loading…
Marker Therapeutics, Inc. is projected to rise to $1.45 by 2027, a 0% move from its current price of $1.45. MRKR is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.41 | $1.45 | $1.49 | +0.05% |
| May 30 | $1.40 | $1.45 | $1.51 | +0.09% |
| May 31 | $1.38 | $1.45 | $1.52 | +0.14% |
| Jun 1 | $1.38 | $1.45 | $1.53 | +0.18% |
| Jun 2 | $1.37 | $1.45 | $1.55 | +0.23% |
| Jun 3 | $1.36 | $1.45 | $1.56 | +0.28% |
| Jun 4 | $1.35 | $1.45 | $1.56 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.35 | $1.45 | $1.56 | +0.32% |
| Week 2 | $1.32 | $1.46 | $1.62 | +0.65% |
| Week 3 | $1.29 | $1.46 | $1.66 | +0.97% |
| Week 4 | $1.27 | $1.47 | $1.70 | +1.29% |
| Week 5 | $1.25 | $1.47 | $1.73 | +1.62% |
| Week 6 | $1.24 | $1.48 | $1.77 | +1.95% |
| Week 7 | $1.22 | $1.48 | $1.80 | +2.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Marker Therapeutics develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc.
in October 2018. Marker Therapeutics was founded in 1999 and is headquartered in Houston, Texas.
Marker Therapeutics, Inc. (MRKR) is currently priced at $1.40 and operates in the Healthcare sector as a clinical-stage immuno-oncology company.
Its market capitalization is $23.34M and it is ranked 4901 by size, reflecting its smaller float in the market. The asset shows a long-run price outlook that anticipates a bullish trajectory, with the average price trending higher over the coming years and a max forecast in the $10.51 range by 2050.
The forecast presents a path from 2026 onward where the average price rises toward $5.62 by 2050, with a potential max of $10.51 in 2050 and a bullish sentiment from 2029 onward. This suggests meaningful upside if the projections hold, though near-term volatility and risks remain.
A major floor 15.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.1% below — buyers have tended to step in here.
The nearest ceiling, 15.2% above — a clean break opens room to run.
A major ceiling 51.0% above — clearing it would confirm fresh momentum.
Key MRKR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MRKR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.43 | Buy | $1.43 | Buy |
| MA 10 | $1.42 | Buy | $1.43 | Buy |
| MA 20 | $1.45 | Buy | $1.44 | Buy |
| MA 50 | $1.45 | Buy | $1.46 | Sell |
| MA 100 | $1.55 | Sell | $1.45 | Sell |
| MA 200 | $1.32 | Buy | $1.49 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.99 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 10.10 | Neutral |
| Williams %R (14) | -14.29 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -0.68 | Sell |
| Bollinger %B (20,2) | 0.53 | Neutral |
| Stochastic %K (14) | 85.71 | Sell |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 54.01 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 1.44 | Buy |
| ADX (14) | 8.69 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL, with RSI14 at 40. The near-term momentum does not indicate overbought or oversold conditions.
The 50-day simple moving average is listed at $1.45, while the 200-day simple moving average sits at $1.32, illustrating a mild upward drift in price formation unless pulled by broader market moves. Support is identified at $1.39 and resistance at $1.74, offering a defined trading range nearby.
The 30-day price range is between $1.16 and $1.68, indicating a relatively tight band around the current price with room to move within the range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.24 | $1.45 | $1.85 | 0% | Neutral | |
| $1.15 | $1.45 | $1.94 | 0% | Neutral | |
| $1.32 | $1.71 | $2.37 | +18% | Neutral | |
| $1.56 | $2.07 | $2.95 | +43% | Bullish | |
| $1.49 | $2.02 | $2.94 | +39% | Bullish | |
| $1.52 | $2.10 | $3.13 | +45% | Bullish | |
| $1.56 | $2.19 | $3.33 | +51% | Bullish | |
| $1.46 | $2.09 | $3.23 | +44% | Bullish | |
| $1.74 | $2.52 | $3.96 | +74% | Bullish | |
| $1.97 | $2.89 | $4.61 | +99% | Bullish | |
| $2.41 | $3.80 | $6.43 | +162% | Bullish | |
| $3.42 | $6.04 | $11.20 | +317% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.24 | $1.45 | $1.70 | +0.00% |
| June 2026 | $1.23 | $1.45 | $1.74 | -0.17% |
| July 2026 | $1.28 | $1.51 | $1.84 | +4.46% |
| August 2026 | $1.29 | $1.54 | $1.89 | +1.72% |
| September 2026 | $1.25 | $1.49 | $1.86 | -2.82% |
| October 2026 | $1.23 | $1.49 | $1.86 | -0.64% |
| November 2026 | $1.24 | $1.50 | $1.90 | +1.29% |
| December 2026 | $1.20 | $1.46 | $1.85 | -3.07% |
Click any year to see its month-by-month MRKR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MRKR to range from $1.24 to $1.85 through 2026. The $1.45 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The MRKR price prediction for 2027 points to an average of $1.45 (low $1.15, high $1.94) — a potential gain of 0% on today's $1.45. Price action looks broadly range-bound.
In 2028, MRKR is projected to trade between $1.32 and $2.37, averaging $1.71 — a potential gain of +18% from today's $1.45. That is up +18% on the projected 2027 average. A consolidation phase looks the most probable path here.
Marker Therapeutics, Inc.'s 2029 outlook centres on $2.07, within a $1.56 to $2.95 range. That is up +21% on the projected 2028 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2030, MRKR could reach as high as $2.94, with a base case around $2.02 and support toward $1.49 — roughly +39% from $1.45. Buyers look set to stay in control over this stretch.
Expect MRKR to range from $1.52 to $3.13 through 2031. The $2.10 average target implies a +45% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The MRKR price prediction for 2032 points to an average of $2.19 (low $1.56, high $3.33) — a potential gain of +51% on today's $1.45. Buyers look set to stay in control over this stretch.
In 2033, MRKR is projected to trade between $1.46 and $3.23, averaging $2.09 — a potential gain of +44% from today's $1.45. That is -5% versus the projected 2032 average. Momentum favours further upside here.
Marker Therapeutics, Inc.'s 2034 outlook centres on $2.52, within a $1.74 to $3.96 range. That is up +21% on the projected 2033 average. That marks a +74% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, MRKR could reach as high as $4.61, with a base case around $2.89 and support toward $1.97 — roughly +99% from $1.45. Momentum favours further upside here.
Expect MRKR to range from $2.41 to $6.43 through 2040. The $3.80 average target implies a +162% move from current prices. That is up +31% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The MRKR price prediction for 2050 points to an average of $6.04 (low $3.42, high $11.20) — a potential gain of +317% on today's $1.45. Momentum favours further upside here.
Investing $1,000 in MRKR today (≈ 689.655172 MRKR) could be worth
$4,167.69
+$3,167.69 (+317%) by 2050 · US Dollar
Based on the average projected MRKR price of $6.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MRKRwould be worth at today's price.
$1,000 invested in MRKR on May 27, 2025 (≈ 869.565235 MRKR) would be worth
$1,260.87
+$260.87 (+26.1%) today · 1.26× · US Dollar
Based on a MRKR entry price of $1.15 vs. today's $1.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.41 | $1,028.37 | +2.8% |
| 1 month ago | $1.45 | $1,000 | -0.0% |
| 3 months ago | $1.58 | $917.72 | -8.2% |
| 6 months ago | $1.24 | $1,169.35 | +16.9% |
| 1 year ago | $1.15 | $1,260.87 | +26.1% |
| All time (5.0y) ago | $30 | $48.33 | -95.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MRKR forecast.
Our base-case forecast reaches $2.90 around 2040.
Implied market cap at $2.90: $48.35M
Over the multi-year forecast horizon, Marker Therapeutics shows an upward price trajectory. The average price for 2026 is $1.40 and climbs to $1.93 by 2030, with higher min/max levels along the way (min $1.42 in 2030, max $2.83). The predicted ROI rises across years, hitting 37.9 in 2030, 43.2 in 2031, and 48.1 in 2032, before accelerating to 70.7 in 2034, 95.4 in 2035, 156.6 in 2040, and 301.3 in 2050.
Sentiment flips from NEUTRAL in 2026 and 2027 to BULLISH starting in 2029, aligning with an expanding average price and higher price targets into the 2030s and beyond. The max forecast reaches $10.51 in 2050, underscoring substantial upside potential if the longer-term assumptions hold. While the longer horizon suggests meaningful upside, near-term uncertainties and risk remain, and these figures are not guarantees.
Tap a question to reveal the answer.
In 2030 the forecast shows min $1.42, avg $1.93, max $2.83 with an ROI of 37.9 and sentiment BULLISH.
The forecast indicates a bullish long-term trend, with the average price rising to $5.62 by 2050 and an ROI of 301.3 in 2050, though near-term years show neutral or lower ROIs (e.g., 2026 ROI 0 and 2027 ROI -0.2). These are estimates and not guarantees.
The 2031 forecast lists min $1.45, avg $2.01, max $3.01 with an ROI of 43.2 and sentiment BULLISH, indicating a possibility of reaching or exceeding $3 on the upside.
Current price is $1.40. The 30-day range is $1.16 to $1.68, with a nearby support at $1.39 and resistance at $1.74.
Market cap is $23.34M and the rank is 4901.
Marker Therapeutics, Inc. Community Discussion
0Share your Marker Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.